Immunitybio Inc.

09/09/2024 | Press release | Distributed by Public on 09/09/2024 12:37

ImmunityBio Presents Positive Long Term Overall Survival Data in Non Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.